[go: up one dir, main page]

PL3346995T3 - Kompozycje terapeutyczne do leczenia ludzkiego wirusa niedoboru odporności - Google Patents

Kompozycje terapeutyczne do leczenia ludzkiego wirusa niedoboru odporności

Info

Publication number
PL3346995T3
PL3346995T3 PL16798063T PL16798063T PL3346995T3 PL 3346995 T3 PL3346995 T3 PL 3346995T3 PL 16798063 T PL16798063 T PL 16798063T PL 16798063 T PL16798063 T PL 16798063T PL 3346995 T3 PL3346995 T3 PL 3346995T3
Authority
PL
Poland
Prior art keywords
treatment
immunodeficiency virus
human immunodeficiency
therapeutic compositions
therapeutic
Prior art date
Application number
PL16798063T
Other languages
English (en)
Polish (pl)
Inventor
Lei Hong
Benjamin Micah Collman
Joanna M. Koziara
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57346085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3346995(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of PL3346995T3 publication Critical patent/PL3346995T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL16798063T 2015-11-09 2016-11-08 Kompozycje terapeutyczne do leczenia ludzkiego wirusa niedoboru odporności PL3346995T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562253042P 2015-11-09 2015-11-09
US201662399999P 2016-09-26 2016-09-26
EP16798063.0A EP3346995B1 (fr) 2015-11-09 2016-11-08 Compositions thérapeutiques pour le traitement du virus de l'immunodéficience humaine
PCT/US2016/060989 WO2017083304A1 (fr) 2015-11-09 2016-11-08 Compositions thérapeutiques pour le traitement du virus de l'immunodéficience humaine

Publications (1)

Publication Number Publication Date
PL3346995T3 true PL3346995T3 (pl) 2020-03-31

Family

ID=57346085

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16798063T PL3346995T3 (pl) 2015-11-09 2016-11-08 Kompozycje terapeutyczne do leczenia ludzkiego wirusa niedoboru odporności

Country Status (27)

Country Link
US (3) US10548846B2 (fr)
EP (2) EP3346995B1 (fr)
JP (1) JP6621933B2 (fr)
KR (4) KR102606625B1 (fr)
CN (2) CN113546052A (fr)
AU (2) AU2016354007C9 (fr)
BR (1) BR102016026127A2 (fr)
CA (1) CA2948021C (fr)
CL (1) CL2018001199A1 (fr)
CO (1) CO2018004776A2 (fr)
CR (1) CR20180253A (fr)
EA (1) EA201890654A1 (fr)
EC (1) ECSP18033723A (fr)
ES (1) ES2757560T3 (fr)
IL (1) IL258459A (fr)
MX (1) MX2018005729A (fr)
NZ (1) NZ741957A (fr)
PE (1) PE20181207A1 (fr)
PH (1) PH12018501001A1 (fr)
PL (1) PL3346995T3 (fr)
PT (1) PT3346995T (fr)
SG (1) SG11201802983TA (fr)
SI (1) SI3346995T1 (fr)
SV (1) SV2018005682A (fr)
TW (2) TW202220660A (fr)
UY (1) UY36981A (fr)
WO (1) WO2017083304A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12019501848A1 (en) 2012-12-21 2020-03-02 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
NO2717902T3 (fr) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
ES2892123T3 (es) 2014-12-26 2022-02-02 Univ Emory Derivados antivíricos de N4-hidroxicitidina
EP3346995B1 (fr) * 2015-11-09 2019-08-28 Gilead Sciences, Inc. Compositions thérapeutiques pour le traitement du virus de l'immunodéficience humaine
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
JP2020530024A (ja) * 2017-08-09 2020-10-15 ヴィーブ ヘルスケア カンパニー 組み合わせ並びにその使用及び治療
US20200246351A1 (en) * 2017-08-09 2020-08-06 Viiv Healthcare Company Combinations and uses and treatments thereof
ES2995458T3 (en) 2017-12-07 2025-02-10 Univ Emory N4-hydroxycytidine derivative and anti-viral uses related thereto
WO2019165374A1 (fr) 2018-02-26 2019-08-29 Gilead Sciences, Inc. Composés de pyrrolizine substitués en tant qu'inhibiteurs de réplication du virus de l'hépatite b
CA3113011A1 (fr) * 2018-09-19 2020-03-26 Gilead Sciences, Inc. Inhibiteurs d'integrase pour la prevention du vih
CN111096954B (zh) * 2018-10-29 2022-09-16 江苏豪森药业集团有限公司 一种用于抗病毒感染的药物组合物及制备方法
EP3653629A1 (fr) * 2018-11-16 2020-05-20 Sandoz AG Sels d'addition d'acide d'un inhibiteur de transfert de brins de l'intégrase
CN111686082A (zh) * 2019-03-11 2020-09-22 苏州特瑞药业有限公司 一种富马酸磷丙替诺福韦制剂及其制备方法
CN119174736A (zh) * 2024-09-09 2024-12-24 安徽贝克生物制药有限公司 一种三联复方片及制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1331208A (zh) 2000-06-30 2002-01-16 上海博德基因开发有限公司 一种新的多肽——人肿瘤坏死因子受体21.45和编码这种多肽的多核苷酸
DK1301519T4 (da) 2000-07-21 2021-12-20 Gilead Sciences Inc Prodrugs af phosphonatnukleotidanaloger og fremgangsmåder til udvælgelse og fremstilling heraf
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
EP1549315A4 (fr) 2002-09-11 2007-05-23 Merck & Co Inc Composes de dihydroxypyridopyrazine-1,6-diones utiles en tant qu'inhibiteurs de l'integrase du vih
AU2004206821C1 (en) 2003-01-14 2009-10-01 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
EP1790638B1 (fr) 2004-09-15 2013-04-03 Shionogi Co., Ltd. Dérivé de carbamoylpyridone ayant une activité d'inhibition de la vih intégrase
LT3372281T (lt) 2005-04-28 2021-12-10 Viiv Healthcare Company Policiklinis karbamoilpiridono darinys, turintis živ integrazės inhibitorinį aktyvumą
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
CA2847871C (fr) 2005-12-30 2016-07-26 Gilead Sciences, Inc. Procedes pour l'amelioration de la pharmacocinetique d'inhibiteurs de l'integrase vih
WO2008043829A2 (fr) 2006-10-14 2008-04-17 Boehringer Ingelheim International Gmbh Procédé de traitement d'une infection par le vih-1 par l'administration combinée de névirapine, de ténofovir et d'emtricitabine
WO2010091197A2 (fr) 2009-02-06 2010-08-12 Gilead Sciences, Inc. Pastilles destinées à une thérapie combinée
EA201691695A1 (ru) 2010-11-19 2017-11-30 Джилид Сайэнс, Инк. Терапевтические композиции, содержащие рилпивирин hcl и тенофовира дизопроксилфумарат
SI2729130T1 (en) 2011-07-07 2018-03-30 Janssen Sciences Ireland Uc Combined formulations of darunavir
EA027768B1 (ru) 2011-08-16 2017-08-31 Джилид Сайэнс, Инк. Тенофовир алафенамида гемифумарат
WO2013115916A1 (fr) 2012-02-03 2013-08-08 Gilead Sciences, Inc. Polythérapie comprenant le gs-7340 et le cobicistat destinée à être utilisée dans le traitement d'infections virales
JP6059255B2 (ja) * 2012-02-03 2017-01-11 ギリアード サイエンシス インコーポレーテッド ウイルス感染の処置における使用のためのテノホビルアラフェンアミドヘミフマル酸塩とコビシスタットを含む併用療法
US20140221355A1 (en) 2012-12-21 2014-08-07 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
PH12019501848A1 (en) 2012-12-21 2020-03-02 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
NO2865735T3 (fr) * 2013-07-12 2018-07-21
US20160184332A1 (en) * 2013-08-14 2016-06-30 Ratiopharm Gmbh Medicament comprising a pharmaceutical combination of drugs
WO2015039348A1 (fr) 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Composés hétérocycliques tétracycliques utiles comme inhibiteurs de l'intégrase du vih
NO2717902T3 (fr) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
CA2921336A1 (fr) 2015-06-30 2016-12-30 Gilead Sciences, Inc. Formulations pharmaceutiques
ES2925246T3 (es) 2015-06-30 2022-10-14 Gilead Sciences Inc Formulaciones farmacéuticas que comprenden tenofovir y emtricitabina
EP3346995B1 (fr) * 2015-11-09 2019-08-28 Gilead Sciences, Inc. Compositions thérapeutiques pour le traitement du virus de l'immunodéficience humaine
KR102100436B1 (ko) 2018-10-30 2020-04-13 울산과학기술원 강자성 원소 치환형 상온 다강성 물질 및 그 제조 방법

Also Published As

Publication number Publication date
CR20180253A (es) 2018-07-16
AU2016354007A8 (en) 2018-06-14
KR20230015512A (ko) 2023-01-31
US10548846B2 (en) 2020-02-04
CN108348473B (zh) 2021-06-18
ES2757560T3 (es) 2020-04-29
AU2016354007C1 (en) 2020-09-10
HK1256093A1 (zh) 2019-09-13
EA201890654A1 (ru) 2018-10-31
EP3346995A1 (fr) 2018-07-18
AU2016354007A1 (en) 2018-05-10
AU2020200995B2 (en) 2022-04-07
IL258459A (en) 2018-05-31
KR102153996B1 (ko) 2020-09-09
CL2018001199A1 (es) 2018-09-28
KR20180067702A (ko) 2018-06-20
JP6621933B2 (ja) 2019-12-18
UY36981A (es) 2017-06-30
AU2016354007C9 (en) 2020-10-01
SG11201802983TA (en) 2018-05-30
BR102016026127A2 (pt) 2017-05-16
TWI737647B (zh) 2021-09-01
PH12018501001A1 (en) 2018-12-17
AU2020200995A1 (en) 2020-02-27
PT3346995T (pt) 2019-11-22
KR20240095320A (ko) 2024-06-25
NZ741957A (en) 2019-04-26
MX2018005729A (es) 2018-08-09
TW201726139A (zh) 2017-08-01
US20210052502A1 (en) 2021-02-25
ECSP18033723A (es) 2018-05-31
TW202220660A (zh) 2022-06-01
WO2017083304A1 (fr) 2017-05-18
CN113546052A (zh) 2021-10-26
AU2020200995B9 (en) 2022-04-28
US20170189337A1 (en) 2017-07-06
PE20181207A1 (es) 2018-07-23
HK1256903A1 (en) 2019-10-04
US20220378798A1 (en) 2022-12-01
US11744802B2 (en) 2023-09-05
SV2018005682A (es) 2018-08-15
CA2948021A1 (fr) 2017-05-09
CA2948021C (fr) 2024-06-18
AU2016354007B2 (en) 2019-11-14
KR102606625B1 (ko) 2023-11-27
EP3632415A1 (fr) 2020-04-08
CO2018004776A2 (es) 2018-06-20
WO2017083304A8 (fr) 2018-04-19
KR20200106222A (ko) 2020-09-11
SI3346995T1 (sl) 2019-11-29
JP2018532811A (ja) 2018-11-08
EP3346995B1 (fr) 2019-08-28
CN108348473A (zh) 2018-07-31

Similar Documents

Publication Publication Date Title
IL258459A (en) Medical preparations for the treatment of the human immunodeficiency virus
IL263641A (en) Pharmaceutical preparations and their use for the treatment of cancer and autoimmune diseases
PT3212233T (pt) Terapia combinada para o tratamento de doenças
PL3349783T3 (pl) Kompozycje i sposoby do leczenia chorób
PT3286166T (pt) Inibidores de replicação do vírus da imunodeficiência humana
EP3102225A4 (fr) Polythérapie pour le traitement d'infections par le vhb
EP4591936A3 (fr) Traitement de maladies respiratoires
IL257355B (en) Selection of patients for combined treatment
IL271965A (en) Preparations containing a neoantigenic vaccine for the treatment of cancer
GB201516905D0 (en) Treatment of Neurodegenerative diseases
ZA201705847B (en) Treatment of pain
IL259710A (en) Preparations and methods for the treatment of Davidson's disease (microvillus inclusion disease) and related diseases
SG11201605440TA (en) Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome
PT3302499T (pt) Tratamento de doenças mitocondriais
SG11201704169WA (en) Pharmaceutical composition for treatment or palliation of elderly or end-stage cancer patient
IL256919A (en) Pharmaceutical compositions useful for the treatment of tissue damage
IL252543A0 (en) Compounds for the treatment of degenerative retinal tissues
GB201601456D0 (en) Improvements relating to retinal treatment
SG11201703330YA (en) Iminosugars useful for the treatment of viral diseases
IL257689A (en) Pharmacological preparations and methods for the treatment of diseases associated with hypoxia
IL247369A0 (en) Compounds and methods for the treatment of bone diseases
HK40058742B (en) Treatment of respiratory diseases
GB201714241D0 (en) Pharmaceutical compositions for the treatment of proteinopathies
GB201501800D0 (en) Treatment of medical conditions
GB201621398D0 (en) Treatment of emt-associated disease